Related Experiment Videos
[Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study]
Insights
Ramipril effectively lowers blood pressure in patients with mild to moderate hypertension. This antihypertensive medication demonstrated good tolerance and high physician-rated effectiveness in a large clinical trial.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a prevalent cardiovascular risk factor.
- Effective and well-tolerated antihypertensive medications are crucial for patient management.
Purpose of the Study:
- To investigate the efficacy and tolerance of ramipril in patients with mild to moderate hypertension.
- To assess the antihypertensive effect of ramipril over a twelve-week period.
Main Methods:
- A twelve-week, open-label trial involving 685 patients with mild to moderate hypertension.
- Ramipril was administered, with blood pressure monitored at 4, 8, and 12 weeks.
- Patient outcomes were assessed for efficacy, tolerance, and adverse events.
Main Results:
- Ramipril demonstrated a significant and progressive drop in blood pressure, particularly with monotherapy.
- The medication was well-tolerated, with only 11% reporting undesirable effects, and three discontinuing due to cough.
- Physicians rated ramipril's effectiveness as very good in 88% and tolerance in 97% of cases.
Conclusions:
- Ramipril is an effective and well-tolerated treatment option for mild to moderate hypertension.
- The study supports the use of ramipril in general practice for managing hypertensive patients.
Abstract:
A twelve-week open trial investigating the effect and tolerance of ramipril in 685 patients with mild to moderate hypertension in 88 clinics mostly of general practitioners (list with the author). The antihypertensive effect was investigated after 4, 8 and 12 weeks. The trial was terminated consistent with the protocol by 501 (73.1%) patients, 36 (5.3%) were eliminated early and in 148 (21.6%) the prescribed protocol was not respected. 413 patients (82.4%) terminated the trial on monotherapy, the remaining 88 (17.6%) had combined treatment from the 8th week onwards. When the trial with monotherapy was terminated the drop of blood pressure was more marked already during the 4th week and this trend proceeded during the 8th and 12th week, while in patients who had combined treatment from the 8th week the authors did not observe a drop of the blood pressure between the 4th and 8th week. The investigated laboratory indicators displayed insignificant changes within the range of normal values. The preparation was well tolerated, the total number of undesirable effects was 11% (three patients discontinued because of a cough). The effectiveness was evaluated by the attending physician as very good in 88%, the tolerance in 97%.